Ensysce Biosciences, Inc.
Other OTCTotal Valuation
Ensysce Biosciences, Inc. carries a market capitalization of 16,902.00, placing it among publicly traded companies globally. Its enterprise value stands at -828,603.00, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 16,902.00 |
| Enterprise Value | -828,603.00 |
Share Statistics
Ensysce Biosciences, Inc. currently has 9.28M shares outstanding.
| Shares Outstanding | 9.28M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Financial Position
Ensysce Biosciences, Inc. maintains a current ratio of 0.71, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -36.75, indicating conservative leverage, while an interest coverage ratio of -628.07 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.71 |
| Quick Ratio | 0.26 |
| Debt / Equity | -36.75 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | -628.07 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -347.70 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Ensysce Biosciences, Inc.'s stock has declined approximately -96.19377% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.02.
| Beta (5Y) | N/A |
| 52-Week Price Change | -96.19377% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.02 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -11.83M, while operating income came in at -11.84M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -11.84M |
| Pretax Income | -11.79M |
| Net Income | -11.79M |
| EBITDA | -11.83M |
| EBIT | -11.84M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Ensysce Biosciences, Inc. holds 745,482.00 in cash and equivalents against 245,849.00 in total debt, resulting in a net debt position of -499,633.00. Total book value stands at -143.28M, with working capital of -828,275.00 providing operational flexibility.
| Cash & Cash Equivalents | 745,482.00 |
| Total Debt | 245,849.00 |
| Net Debt | -499,633.00 |
| Equity (Book Value) | -143.28M |
| Book Value Per Share | N/A |
| Working Capital | -828,275.00 |
Cash Flow
Ensysce Biosciences, Inc. produced -9.60M in operating cash flow over the past twelve months.
| Operating Cash Flow | -9.60M |
| Capital Expenditures | N/A |
| Free Cash Flow | -9.60M |
| FCF Per Share | N/A |
Scores
Ensysce Biosciences, Inc. posts an Altman Z-Score of -111.01, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -111.01 |